Pricing Log in Create free account
Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue
+13.3%
EPS
−9.42%
Free cash flow
+364.6%
Total debt
−4.00%

Quarter to September 2026, against a year earlier

67.28 0.29 −0.43%
Market cap
$39.0B
P/E
37.6×
Fwd P/E
27.3×
Dividend yield
1.37%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
41/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Royalty Pharma PLC 8-K filed May 28, 2026

Period ended May 22, 2026 · Filed · accepted 4:01 PM ET · Document on sec.gov · Filing index

1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov